AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02092480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: If I Were Jack
Description: The If I Were Jack intervention is a classroom-based RSE resource designed to be delivered by teachers over four weeks. It is composed of: (i) An interactive video drama which asks pupils to put themselves in Jack's shoes and consider how they would feel and what they would do if they were Jack; (ii) Classroom materials for teachers containing detailed lesson plans with specific classroom-based and homework activities; (iii) 60-minute training session for teachers wishing to implement the intervention; (iv) 60-minute information and discussion session for parents/guardians delivered by RSE teachers; (v) Brochures and factsheets about the intervention and unintended teenage pregnancy for schools, teachers, teacher trainers, young people and parents.
Study NCT04535323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04535323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04535323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Autologous Platelet-rich Plasma
Description: Given via injection
Study NCT01100060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin (AZ) microsphere
Description: AZ microsphere (2000 mg) single dose on Day 1.
Study NCT01100060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test chloroquine (CQ) formulation
Description: Test CQ formulation, 620 mg CQ base, single dose on Day 1.
Study NCT01100060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin (AZ)
Description: AZ IR 4 x 500 mg tablets, single dose on Day 1.
Study NCT01100060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chloroquine (CQ)
Description: CQ 2 x 500 mg (600 mg CQ base) tablets, single dose on Day 1
Study NCT02204137 — intervention group
Intervention type: OTHER
Intervention: Falls Risk Questionnaire
Study NCT02204137 — intervention group
Intervention type: OTHER
Intervention: Cancer and Aging Research Group Geriatric Assessment
Study NCT02204137 — intervention group
Intervention type: OTHER
Intervention: Falls Efficacy Scale-International (FES-1)
Study NCT02204137 — intervention group
Intervention type: OTHER
Intervention: Health Related Quality of Life using the Functional Assessment of Cancer Therapy - Gynecologic Oncology Group Neurotoxicity Scale (FACT GOG/NTX)
Study NCT00728117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: feeding
Description: Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
Study NCT00728117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fasting
Description: Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
Study NCT02220504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment discontinuation
Description: Withdrawal of antipsychotic medication to stabilized patients.
Study NCT02220504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance antipsychotic treatment
Description: Maintenance antipsychotic medication to stabilized patients.
Study NCT01233882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Single dose of 200 mg of bosutinib in subjects with normal renal function
Study NCT01233882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Single dose of 200 mg of bosutinib in subjects with mild renal impairment
Study NCT04259203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Erickson hypnosis
Description: Erickson hypnosis sessions performed by an experienced hypnotherapist, according to a pre-established protocol : 5 sessions (1 per week). Between each session : exercise of auto-hypnosis by the patient himself, at home
Study NCT03762239 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Purifying the air with a Pure Airbox device (Zonair 3D)
Description: Purifying the air of the classroom where the experiment is conducted using a Pure Airbox device (Zonair 3D)
Study NCT03762239 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Using a sham air purifier (same device without filters)
Description: Use the air purifier (Pure Airbox, Zonair 3D) without filters in the classroom where the experiment is conducted
Study NCT01233882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Single dose of 200 mg of bosutinib in subjects with moderate renal impairment
Study NCT01233882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Single dose of 200 mg of bosutinib in subjects with severe renal impairment
Study NCT00366301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine injection
Description: Once daily for 14 weeks
Study NCT00366301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Up to 4 pils per day (2g per day) maximum
Study NCT00366301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pill
Description: Up to 4 pills per day
Study NCT00366301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Up to 4 pills per day
Study NCT02710695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This group will receive a standardized 10 minute discussion.
Study NCT02710695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: This group will receive a standardized 10 minute discussion
Study NCT02579018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One hour supervised exercise session
Description: All participants will participate in a one hour supervised exercise session. Participants will wear a physical activity monitor during the assessment for continuous monitoring of heart rate. Short, intense bouts of exercise will be interspersed with rest periods.
Study NCT02207439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir (Viracept®) 1250 mg
Description: Period 1: Nelfinavir Lead-In (1250 mg bid, 7-14 days).
Study NCT02207439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: Period 2: Concurrent Chemoradiation (70 Gy over 7 weeks) with Nelfinavir (1250 mg bid)
Study NCT01964521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Transfer Ag
Description: A soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
Study NCT01091623 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training
Study NCT03452605 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cocoa flavanol supplementation
Description: cocoa flavanols (containing 196 mg epicatechin)
Study NCT03452605 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cocoa flavanol supplementation
Description: cocoa flavanols (containing 196 mg epicatechin)
Study NCT03458559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radium-223 chloride
Description: Intravenously 50 kBq/kg every 4 weeks. Total: 6 administrations
Study NCT03458559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhenium-188-HEDP
Description: Intravenously 40 MBq/kg every 8 weeks. Total: 3 administrations
Study NCT00476619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: erythropoeitin
Description: Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
Study NCT02092246 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound machine
Description: Use of ultrasound machine guidance for accurate needle placement into the knee joint
Study NCT02092246 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unguided injection
Description: Needle placement will take place without ultrasound machine guidance
Study NCT03485274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vortioxetine
Description: oral medication taken once daily
Study NCT03485274 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Any pharmacological or non-pharmacotherapy modalities other than use of vortioxetine
Study NCT03446105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based behavioral intervention
Description: Achieving Wellness After Kancer in Early life (AWAKE) is a behavioral intervention that includes a smartphone app and coaching. AWAKE contains eight modules, and participants will complete the one module every week. App functioning will facilitate weekly homework assignments and include health education messaging, the ability to track progress toward goals over time via self-monitoring and graphical depictions of progress, audio-recordings of guided imagery exercises and relaxation exercises (e.g., progressive muscle relaxation), videos of topic-related inspirational material, and a portal for interacting with the coach. The coach will call each intervention participant weekly. Each coaching session will last roughly 30 minutes and involve four segments that will correspond to the module for the week. The coach will send daily text messages to participants encouraging their goal pursuits and providing other sources of support related to that week's homework.
Study NCT03446105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control group
Description: The attention control group will receive the same components as the intervention group, but the educational modules will contain different content than those receiving the AWAKE intervention.
Study NCT01663779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided radial artery catheterization.
Description: Radial artery catheters will be placed with the assistance of bedside ultrasound.
Study NCT01663779 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blind insertion of radial artery catheterization
Description: Radial artery catheters will be placed by the palpation technique only.
Study NCT03360409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACD
Description: Undertake anterior cervical discectomy without fusion
Study NCT03360409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACDF
Description: anterior cervical discectomy with fusion
Study NCT03360409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACDA
Description: anterior cervical discectomy with arthroplasty
Study NCT03065088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aLIFE
Description: The aLiFE programme is taught by an instructor during six home visits and 3 phone calls during the 6-month intervention period. The programme will be personalised by use of an initial balance and strength assessment (aLiFE assessment tool). The participants assigns activities to his or her daily activities, and during subsequent home visits, the number of activities and task demands are upgraded. Participants will be taught how to select opportunities themselves to embed activities into their individual daily routine, and how to progress over time.
Study NCT03065088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eLIFE
Description: The eLIFE includes a personalised ICT-administered training schedule using the activities developed in aLiFE, delivered in the form of video clips, pictures and text/verbal instructions on a smartphone and smartwatch application. Personalisation of activity content will be decided based on a phenotype tool and initial difficulty level is decided through the aLiFE assessment tool. In addition, a virtual instructor teaches the participants how to carry out the eLiFE programme. The user receives motivational messages and feedback, and there will be a possibility for social interaction between the participants. The instructors teach the eLiFE participants the programme during 4 home visits and 3 phone calls during the 6 month intervention period.
Study NCT03065088 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: The control group follows the World Health Organization's recommendations of physical activity. The control participants will receive one home visit and be given a written letter with the activity recommendations.
Study NCT02410798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TransLoc electrode
Description: Patients will have 2 electrodes placed in either side of the diaphragm (total 4 electrodes) during their primary surgery.
Study NCT00464516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once daily for 14 days orally
Study NCT00464516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol
Description: once daily for 14 days orally
Study NCT02050919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin Hydrochloride
Description: Given IV
Study NCT02050919 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT02674360 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SDM Training
Study NCT02050919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT01361620 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: aspirin
Description: aspirin 81mg, 7-10 days
Study NCT03222258 — intervention group
Intervention type: BEHAVIORAL
Intervention: Early palliative care
Description: Palliative Care Team provide a self-learning booklet, medical treatment and consultation about Advance Care Planning with chemotherapy by oncologist.
Study NCT03222258 — intervention group
Intervention type: BEHAVIORAL
Intervention: Routine hospice care
Description: Palliative Care Team provide a routine hospice care the same as other patients who doesn't participate this study after the chemotherapy is totally terminated
Study NCT03942380 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Liquid biopsy
Description: The intervention is a liquid biopsy as a blood sample taken in a peripheral vein. The blood samples are analyzed for cell free DNA, RNA and HPV-DNA
Study NCT01900574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab will be administered subcutaneously. For participants weighing less than 45 kg, the dose of golimumab at Week 0 will be 90 mg/m2 (up to 200 mg) and 45 mg/m2 (up to 100 mg) at Weeks 2, 6, and 10. For participants weighing 45 kg or more, the dose of golimumab at Week 0 will be 200 mg and 100 mg at Weeks 2, 6, and 10. From Week 14, the dose of golimumab will be 45 mg/m2 and 100 mg, every 4 weeks for participants weighing less than 45 kg and 45 kg or more, respectively. From Week 18, participants weighing 45 kg or more have the option to administer golimumab at home after being properly trained. At Week 14 or at any time after, the participants have the option to decrease their dose of golimumab to 50 mg (weighing 45 kg or more) or 22.5 mg/square meter (less than 45 kg) at the discretion of the investigator. A single dose increase back to 100 mg or 45 mg/m2 is permitted based on the investigator's assessment of an increase in a participant's ulcerative colitis disease activity.
Study NCT03176446 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia with traditional technique
Description: Puncture with short needle in the region of the apical third of the tooth to be anesthetized Injection of local anesthetic, with speed 1ml / min
Study NCT03176446 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia with computerized technique
Description: Puncture with short needle in the region of the apical third of the tooth to be anesthetized according to the recommendations of the manufacturer Injection of local anesthetic with computerized anesthesia equipment, with speed 0.5 ml / min
Study NCT03176446 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia with DentalVibe technique
Description: Use of DentalVibe in the apical region of the tooth to be anesthetized according to the manufacturer's guidelines Puncture with short needle enters the tips of the DentalVibe Injection of local anesthetic with traditional carpule, with speed 1 ml / min
Study NCT03176446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topic anesthesia
Description: Application of topical anesthetic for 60 seconds with benzocaine
Study NCT03176446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic
Description: 2% lidocaine with epinephrine 1: 100000 1.8 mL
Study NCT02108145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral metal stent insertion
Study NCT02108145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral metal stent insertion
Study NCT00781534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginseng
Description: Each of the 3 arms will be compared to determine if there is any clinical difference in blood sugars between the 3 groups
Study NCT00781534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginseng
Study NCT00781534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ginsenoside RE
Description: active metabolite of ginseng
Study NCT00781534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sugar pill)
Description: placebo group
Study NCT02050919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02050919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT02050919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study NCT00076752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Conditioning and transplant regimen: 30 mg/m\^2 day intravenous infusion over 30 minutes daily, 4 days (transplant days -6, -5, -4, -3)
Study NCT00076752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Priming regimen: 2000 mg/m\^2 intravenous infusion over 2 hours, day 2. Conditioning and transplant regimen: 1200 mg/m\^2 day intravenous infusion daily, 4 days (-6, -5, -4, -3).
Study NCT00076752 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituxan (rituximab)
Description: Priming regimen: 375 mg/m\^2 intravenous day 1, 4. Conditioning and transplant regimen: 750 mg/m\^2 intravenous infusion, day -7.
Study NCT00076752 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Priming regimen: 10 micrograms/kg/day subcutaneous, starting day 6. Conditioning and transplant regimen: 5 micrograms/kg/day subcutaneous, day +1 until ANC >500 microliters.
Study NCT00076752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Priming regimen:1000 mg intravenous over 30 minutes, day 1.
Study NCT00076752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Lymphoablative regimen using cyclophosphamide, rituximab, and fludarabine followed by a CD34 cell selected autologous stem cell transplant.
Study NCT00076752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Standard human immunology research laboratory ex vivo studies.
Study NCT00076752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Day 0, product will be infused rapidly intravenously after premedication with diphenhydramine 25-60 mg orally or intravenous.
Study NCT00076752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Conditioning and transplant regimen 25-50 mg orally or intravenously.
Study NCT00076752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Priming regimen: 600 mg/m\^2 intravenous immediately prior to cyclophosphamide and repeat at 4 and 7 hours after the first dose, day 2. Conditioning and transplant regimen:1200 mg/m\^2 per day continuous 24 hour intravenous infusion, daily for 4 days, start concurrently with the start of cyclophosphamide.
Study NCT01864915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride 2mg daily starting three days before the colon capsule study (total of 4 doses with the last at 0800hrs on day of colon capsule study)
Study NCT02829333 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: general anesthesia and patient controlled intravenous analgesia
Description: Patients receive general anesthesia intraoperative period and continuous intravenous analgesia postoperation
Study NCT02829333 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: spinal anesthesia and continuous postoperative epidural analgesia
Description: Patients receive spinal anesthesia intraoperative period and continuous epidural analgesia postoperation